Evidence map›Paper›PMID 35253773›Full record

ArticleJournal of Huntington's disease2022

Safety and Feasibility of Research Lumbar Puncture in Huntington's Disease: The HDClarity Cohort and Bioresource.

Filipe B Rodrigues, Gail Owen, Swati Sathe, Elena Pak, Dipinder Kaur, Anka G Ehrhardt, Sherry Lifer, Jenny Townhill, Katarzyna Schubert, Blair R Leavitt and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Huntington's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Review
  3. [Gene Therapy for Huntington Disease].Fortschritte der Neurologie-Psychiatrie · 2023
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 4 countries.

Filipe B RodriguesUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
Gail OwenUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
Swati SatheCHDI Management/CHDI Foundation, Princeton, NJ, USA.
Elena PakCHDI Management/CHDI Foundation, Princeton, NJ, USA.
Dipinder KaurCHDI Management/CHDI Foundation, Princeton, NJ, USA.
Anka G EhrhardtCHDI Management/CHDI Foundation, Princeton, NJ, USA.
Sherry LiferCHDI Management/CHDI Foundation, Princeton, NJ, USA.
Jenny TownhillEnroll-HD platform, European Huntington's Disease Network, University Hospital of Ulm, Ulm, Germany.
Katarzyna SchubertUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
Blair R LeavittCentre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Mark GuttmanDivision of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Jee BangDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jan LewerenzDepartment of Neurology, Ulm University, Ulm, Germany.
Jamie LeveyCHDI Management/CHDI Foundation, Princeton, NJ, USA.
HDClarity Investigators
Cristina SampaioCHDI Management/CHDI Foundation, Princeton, NJ, USA.
Edward J WildUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
CHDI Foundation · USNational Hospital for Neurology and Neurosurgery · GBUniversity College London · GBEuropean Huntington's Disease NetworkJohns Hopkins Medicine · USUniversität Ulm · DEUniversity Hospital Ulm · DEUniversity of British Columbia · CAUniversity of Toronto · CA

Funding

Medical Research Council MR/M008592/1
6 · The paper itself

Abstract

backgroundBiomarkers are needed to monitor disease progression, target engagement and efficacy in Huntington's disease (HD). Cerebrospinal fluid (CSF) is an ideal medium to research such biomarkers due to its proximity to the brain.

objectiveTo investigate the safety and feasibility of research lumbar punctures (LP) in HD.

methodsHDClarity is an ongoing international biofluid collection initiative built on the Enroll-HD platform, where clinical assessments are recorded. It aims to recruit 1,200 participants. Biosamples are collected following an overnight fast: blood via venipuncture and CSF via LP. Participants are healthy controls and HD gene expansion carriers across the disease spectrum. We report on monitored data from February 2016 to September 2019.

resultsOf 448 participants screened, 398 underwent at least 1 sampling visit, of which 98.24% were successful (i.e., CSF was collected), amounting to 10,610 mL of CSF and 8,200 mL of plasma. In the total 572 sampling visits, adverse events were reported in 24.13%, and headaches of any kind and post-LP headaches in 14.86% and 12.24%, respectively. Frequencies were less in manifest HD; gender, age, body mass index and disease burden score were not associated with the occurrence of the events in gene expansion carriers. Headaches and back pain were the most frequent adverse events.

conclusionHDClarity is the largest CSF collection initiative to support scientific research into HD and is now stablished as a leading resource for HD research. Our data confirm that research LP in HD are feasible and acceptable to the community, and have a manageable safety profile.

Indexed as

Huntington DiseaseBiomarkersFeasibility StudiesHeadacheHumansSpinal PunctureBiomarkersbiomarkersbloodcerebrospinal fluidcohort studiesHuntington’s diseasespinal puncture

Identifiers

PMID35253773
PMCPMC7616897
OpenAlexW4220797998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.